Darby 3.0 automates patient intake workflows from fax to EMR, helping HME providers scale without expanding teams
WATERLOO, Iowa, June 11, 2025 /PRNewswire/ — Darby, a leading provider of AI-powered automation for the home medical equipment (HME) industry, today announced the launch of Version 3.0 of its flagship platform at the 2025 Heartland Conference hosted by VGM. The enhanced suite delivers advanced AI capabilities designed to streamline patient intake operations.
Version 3.0 represents a significant leap forward in Darby’s mission to transform how home medical equipment companies manage their operations, from initial patient intake through payer qualification and compliance reporting. The new release employs artificial intelligence and machine learning technologies to automate complex workflows that have traditionally required extensive manual processing.
“Version 3.0 delivers a complete transformation of the HME intake workflow,” said Robin Y. Smith, CEO of Darby. “With fully automated fax processing, improved AI accuracy for payer qualification, and headless EMR uploads for qualified orders, we’ve eliminated many manual touchpoints in these workflows from referral to patient setup.”
Key capabilities in Version 3.0 include:
The Heartland Conference brings together hundreds of HME professionals, manufacturers, and partners to explore industry innovations. Darby’s participation at the conference reinforces the company’s commitment to supporting the VGM community and advancing the broader HME ecosystem.
About Darby
Darby specializes in AI and automation solutions designed specifically for the home medical equipment industry. Darby’s software is SOC 2 Type II certified and HIPAA compliant. Backed by leading healthcare technology investors including Underscore VC, Flare Capital Partners and January Ventures, Darby serves HME customers nationwide and is committed to helping providers modernize their operations and scale efficiently.
SOURCE Darby Inc
The Houston Business Journal's Most Admired CEO Awards recognize chief executive officers who exemplify exceptional…
Doptelet Sprinkle (avatrombopag) was approved as an effective formulation for children one year to less…
Results show biopsy-proven resolution of BK polyomavirus nephropathy in kidney transplant recipients No safety or tolerability…
EMA’s CHMP issued an opinion not to recommend Elevidys™ (delandistrogene moxeparvovec) for the treatment of…
Pending European Commission (EC) approval, Alhemo® will become available to all adult and paediatric patients…
Sujata Setia, Mithail Afrige Chowdhury and Steve Gschmeissner awarded £10,000 each for images exploring domestic…